Evaluating a Novel Human Fibrinogen Concentrate (BT524) for Congenital Fibrinogen Deficiency
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Excited to share our new publication evaluating a novel human fibrinogen concentrate (BT524) for the treatment of congenital fibrinogen deficiency!
This fibrinogen concentrate includes three independent virus inactivation and removal steps to ensure maximum viral safety.
In this prospective Phase I/III trial, BT524 was investigated in 27 patients (15 adults and 12 children) with congenital afibrinogenemia or severe hypofibrinogenemia:
- Single-dose administration (70 mg/kg) effectively increased fibrinogen antigen levels from undetectable to therapeutic levels
- Half-life: 67.9 hours (FiAg) and 60.3 hours (FiAc) – providing sustained hemostatic coverage
- Significant improvement in clot firmness (FIBTEM MCF +11.1 mm, p < 0.0001) within 1 hour
- Excellent safety profile – only one mild treatment-related adverse event (increased D-dimer), with no thromboembolic events, hypersensitivity reactions, or inhibitor development.
This new fibrinogen concentrate demonstrates excellent pharmacokinetics while providing an outstanding safety and tolerability profile across all age groups.
An important step forward for patients with this ultra-rare bleeding disorder, and a important improvement in the evolution of fibrinogen replacement therapy.
Congratulations to the study team, the co-authors and Biotest— more exciting work ahead!”
Read the full article here.
Article: Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency
Authors: Claudia Djambas Khayat, Amal El-Beshlawy, Balkis Meddeb, Abderrahim Khelif, Wolfgang Miesbach, Sonia Adolf, Heike Boehm, Silke Aigner, Salomon Abraha , Fabian Bohlaender, Joerg Schuettrumpf
Stay updated on all scientific advances Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda